Everything below concerns actin-binding motif. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-14. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
=== Constitutional framework and term length === The Constitution of the Bolivarian Republic of Venezuela, adopted in 1999, sets the presidential term at six years. Article 230 establishes the length of the term, while a 2009 constitutional amendment removed term limits for the presidency and other elected offices, allowing indefinite re-election. Article 231 provides that the president-elect must take office on 10 January of the first year of the term by swearing an oath before the National Assembly, or before the Supreme Tribunal of Justice when circumstances prevent inauguration before the legislature. Article 233 regulates the "absolute absence" of the president (due to death, resignation, removal by the TSJ, permanent incapacity, abandonment of office or recall by referendum). If such an absence occurs in the first four years of the term, a new presidential election must be called within 30 days and the executive vice-president assumes the presidency on an interim basis; in the last two years, the executive vice-president completes the term. If the president is only deemed "temporarily unavailable", the executive vice-president may temporarily assume the presidency for 90 days, and—subject to the approval of the National Assembly—this interim period may be extended by another 90 days, for a total of six months.
Roman A. Zubarev (born 1963) is a Russian-Swedish chemist and professor of medical proteomics in the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, Stockholm, Sweden. His research spans mass spectrometry, proteomics, origin-of-life chemistry, disease biomarker discovery, and related fields.
Iran dismisses a peace plan proposed by the U.S., calling the demands "excessive". The White House warns Iran that Donald Trump will "ensure they are hit harder than ever before" if the country refuses to accept defeat. The U.S. Supreme Court unanimously holds that internet service providers are not liable for the copyright infringement of their users if the ISP did not intend its services to be used for infringement. Trump signs an executive order requiring proof of U.S. citizenship for voter registration.
Sources: en.wikipedia.org
Short-acting insulin analogues are modified forms of recombinant human insulin designed to enhance subcutaneous absorption and accelerate glycemic control. In standard insulin formulations, regular insulin monomers naturally aggregate into hexamers, a configuration that delays absorption and prolongs the onset of action. Before entering the bloodstream, these hexamers must dissociate into dimers and then monomers, which slows their availability for glucose regulation. To address this limitation, insulin analogues have been engineered to maintain a monomeric or dimeric configuration, allowing for faster absorption and reducing the time to onset to approximately 5 to 15 minutes. Insulin lispro, insulin aspart, and insulin glulisine are the most widely used short-acting insulin analogues. These formulations are structurally identical to human insulin, except for amino acid substitutions at one or two positions, which modify their stability and absorption characteristics. Insulin lispro, which was first approved in 1996 and marketed as Humalog among others, works by reversing the final lysine and proline residues on the C-terminal end of the B-chain. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. Clinical studies have demonstrated that the use of insulin lispro instead of regular insulin can reduce hypoglycemia incidence and improve glycemic control.
=== Prelude to the conflict === One 2006 cable reported that Ruslan Khasbulatov was responsible for bombing of Sukhumi in 1993 when Eduard Shevardnadze was personally defending the city. The cables suggested that Russia had been at war with Georgia since 2004. According to a leaked diplomatic cable, the US diplomat Kurt Volker in 2006 had rationalized to Russian deputy Foreign Minister Alexander Grushko as to why the secession of Kosovo should be viewed as an isolated case and should not be transferred to other conflicts. Grushko, on the other hand, made clear the position of Putin who saw Kosovo as a model for the independence of South Ossetia and Abkhazia. Georgian president Saakashvili told United States Under Secretary of State R. Nicholas Burns in 2007 that "Putin was personally committed to removing Abkhazia from Georgia." U.S. dispatches had reported as early as 2007 that Grad missiles and other arms were provided to separatists in South Ossetia and Abkhazia. Russia had engaged in a large variety of covert activities aimed at destabilizing Georgia before the 2008 war. The cables reported that the Russian FSB was in control of South Ossetia.
=== Chronic wounds === A 2015 review found that the evidence supporting the use of electrotherapy in healing pressure ulcers was of low quality, and a 2015 Cochrane review found no evidence that electromagnetic therapy, a subset of electrotherapy, was effective in healing pressure ulcers. Earlier reviews found that, because of low-quality evidence, it was unclear whether electrotherapy increases healing rates of pressure ulcers. By 2014 the evidence supported electrotherapy's efficacy for ulcer healing. Another 2015 Cochrane review found no evidence supporting the use of electrotherapy for venous stasis ulcers.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.